<- Go Home

Alimera Sciences, Inc.

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company’s 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. As of September 16, 2024, Alimera Sciences, Inc. operates as a subsidiary of ANI Pharmaceuticals, Inc.

Market Cap

$301.3M

Volume

123.7K

Cash and Equivalents

$10.8M

EBITDA

$14.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$86.1M

Profit Margin

86.39%

52 Week High

$5.65

52 Week Low

$2.61

Dividend

N/A

Price / Book Value

7.48

Price / Earnings

-17.76

Price / Tangible Book Value

-5.50

Enterprise Value

$362.9M

Enterprise Value / EBITDA

23.91

Operating Income

$2.4M

Return on Equity

34.57%

Return on Assets

0.98

Cash and Short Term Investments

$10.8M

Debt

$72.4M

Equity

$38.8M

Revenue

$99.7M

Unlevered FCF

$5.3M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches